We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Dynavax Technologies Corp | NASDAQ:DVAX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 11.04 | 10.85 | 11.16 | 0 | 01:00:00 |
From May 2019 to May 2024
BERKELEY, CA--(Marketwired - Feb 28, 2014) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the 34th Annual Cowen & Company Health Care Conference in Boston on Tuesday, March 4, 2014 at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time).
Eddie Gray, Chief Executive Officer of Dynavax, will provide a company overview. To access the slide presentation, live webcast, and subsequent archived recording, please visit Dynavax's website at http://investors.dynavax.com/newsevents.cfm.
About Dynavax Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.
Contact: Michael Ostrach Vice President and Chief Business Officer 510-665-7257 Email Contact
1 Year Dynavax Technologies Chart |
1 Month Dynavax Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
